Page 302 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 15 Molecular/Targeted Therapy of Cancer 281

352. Yamazaki J, Jelinek J, Hisamoto S, et al.: Dynamic changes in DNA 373. Rossig L, Urbich C, Bruhl T, et al.: Histone deacetylase activity is
methylation patterns in canine lymphoma cell lines demonstrated essential for the expression of HoxA9 and for endothelial commit-
by genome-wide quantitative DNA methylation analysis, Vet J ment of progenitor cells, J Exp Med, 2005.
VetBooks.ir 353. Ferraresso S, Arico A, Sanavia T, et al.: DNA methylation profiling 374. Phillips A, Bullock T, Plant N: Sodium valproate induces
231:48–54, 2018.
apoptosis in the rat hepatoma cell line, FaO, Toxicology 192:
reveals common signatures of tumorigenesis and defines epigenetic
219–227, 2003.
prognostic subtypes of canine diffuse large B-cell lymphoma, Sci 375. Tang R, Faussat AM, Majdak P, et al.: Valproic acid inhibits pro-
Rep 7:11591, 2017. liferation and induces apoptosis in acute myeloid leukemia cells
354. Fujita M, Kaneda M: DNA methylation inhibitor causes cell expressing P-gp and MRP1, Leukemia 18:1246–1251, 2004.
growth retardation and gene expression changes in feline lym- 376. Roh MS, Kim CW, Park BS, et al.: Mechanism of histone deacety-
phoma cells, J Vet Med Sci 79:1352–1358, 2017. lase inhibitor Trichostatin A induced apoptosis in human osteosar-
355. Harman RM, Curtis TM, Argyle DJ, et al.: A comparative study on coma cells, Apoptosis 9:583–589, 2004.
the in vitro effects of the DNA methyltransferase inhibitor 5-aza- 377. Maeda T, Nagaoka Y, Kawai Y, et al.: Inhibitory effects of cancer
cytidine (5-AzaC) in breast/mammary cancer of different mamma- cell proliferation by novel histone deacetylase inhibitors involve
lian species, J Mammary Gland Biol Neoplasia 21:51–66, 2016. p21/WAF1 induction and G2/M arrest, Biol Pharm Bull 28:849–
356. Noguchi S, Mori T, Igase M, et al.: A novel apoptosis-inducing 853, 2005.
mechanism of 5-aza-2’-deoxycitidine in melanoma cells: demeth- 378. Takai N, Desmond JC, Kumagai T, et al.: Histone deacetylase
ylation of TNF-alpha and activation of FOXO1, Cancer Lett inhibitors have a profound antigrowth activity in endometrial can-
369:344–353, 2015. cer cells, Clin Cancer Res 10:1141–1149, 2004.
357. Flesner BK, Kumar SR, Bryan JN: 6-thioguanine and zebularine 379. Olsen CM, Meussen-Elholm ET, Roste LS, et al.: Antiepilep-
down-regulate DNMT1 and globally demethylate canine malig- tic drugs inhibit cell growth in the human breast cancer cell line
nant lymphoid cells, BMC Vet Res 10:290, 2014. MCF7, Mol Cell Endocrinol 213:173–179, 2004.
358. Thayanithy V, Park C, Sarver AL, et al.: Combinatorial treatment 380. Fortunati N, Catalano MG, Arena K, et al.: Valproic acid induces
of DNA and chromatin-modifying drugs cause cell death in human the expression of the Na+/I- symporter and iodine uptake in
and canine osteosarcoma cell lines, PLoS One 7:e43720, 2012. poorly differentiated thyroid cancer cells, J Clin Endocrinol Metab
359. Hahn NM, Bonney PL, Dhawan D, et al.: Subcutaneous 5-azaciti- 89:1006–1009, 2004.
dine treatment of naturally occurring canine urothelial carcinoma: 381. Gottlicher M: Valproic acid: an old drug newly discovered as inhib-
a novel epigenetic approach to human urothelial carcinoma drug itor of histone deacetylases, Ann Hematol 83(Suppl 1):S91–S92,
development, J Urol 187:302–309, 2012. 2004.
360. Guo Y, Pakneshan P, Gladu J, et al.: Regulation of DNA methyla- 382. Gottlicher M, Minucci S, Zhu P, et al.: Valproic acid defines a
tion in human breast cancer. Effect on the urokinase-type plasmin- novel class of HDAC inhibitors inducing differentiation of trans-
ogen activator gene production and tumor invasion, J Biol Chem formed cells, EMBO J 20:6969–6978, 2001.
277:41571–41579, 2002. 383. Stockhausen MT, Sjolund J, Manetopoulos C, et al.: Effects of the
361. Berger SL: Histone modifications in transcriptional regulation, histone deacetylase inhibitor valproic acid on Notch signalling in
Curr Opin Genet Dev 12:142–148, 2002. human neuroblastoma cells, Br J Cancer 92:751–759, 2005.
362. Jenuwein T, Allis CD: Translating the histone code, Science 384. Thelen P, Schweyer S, Hemmerlein B, et al.: Expressional changes
293:1074–1080, 2001. after histone deacetylase inhibition by valproic acid in LNCaP
363. Zhu P, Martin E, Mengwasser J, et al.: Induction of HDAC2 human prostate cancer cells, Int J Oncol 24:25–31, 2004.
expression upon loss of APC in colorectal tumorigenesis, Cancer 385. Chobanian NH, Greenberg VL, Gass JM, et al.: Histone deacety-
Cell 5:455–463, 2004. lase inhibitors enhance paclitaxel-induced cell death in ovarian
364. Kim MS, Kwon HJ, Lee YM, et al.: Histone deacetylases induce cancer cell lines independent of p53 status, Anticancer Res 24:
angiogenesis by negative regulation of tumor suppressor genes, Nat 539–545, 2004.
Med 7:437–443, 2001. 386. Fuino L, Bali P, Wittmann S, et al.: Histone deacetylase inhibitor
365. Glozak MA, Sengupta N, Zhang X, et al.: Acetylation and deacety- LAQ824 down-regulates Her-2 and sensitizes human breast cancer
lation of non-histone proteins, Gene 363:15–23, 2005. cells to trastuzumab, taxotere, gemcitabine, and epothilone B, Mol
366. Sadoul K, Boyault C, Pabion M, et al.: Regulation of protein turn- Cancer Ther 2:971–984, 2003.
over by acetyltransferases and deacetylases, Biochimie 90:306–312, 387. Kim MS, Blake M, Baek JH, et al.: Inhibition of histone deacety-
2008. lase increases cytotoxicity to anticancer drugs targeting DNA, Can-
367. Marchion DC, Bicaku E, Daud AI, et al.: Valproic acid alters chro- cer Res 63:7291–7300, 2003.
matin structure by regulation of chromatin modulation proteins, 388. Maggio SC, Rosato RR, Kramer LB, et al.: The histone deacety-
Cancer Res 65:3815–3822, 2005. lase inhibitor MS-275 interacts synergistically with fludarabine to
368. Weichert W: HDAC expression and clinical prognosis in human induce apoptosis in human leukemia cells, Cancer Res 64:2590–
malignancies, Cancer Lett 280:168–176, 2009. 2600, 2004.
369. Zgouras D, Becker U, Loitsch S, et al.: Modulation of angiogen- 389. Watanabe K, Okamoto K, Yonehara S: Sensitization of osteosar-
esis-related protein synthesis by valproic acid, Biochem Biophys Res coma cells to death receptor-mediated apoptosis by HDAC inhibi-
Commun 316:693–697, 2004. tors through downregulation of cellular FLIP, Cell Death Differ
370. Qian DZ, Wang X, Kachhap SK, et al.: The histone deacety- 12:10–18, 2005.
lase inhibitor NVP-LAQ824 inhibits angiogenesis and has a 390. Chinnaiyan P, Vallabhaneni G, Armstrong E, et al.: Modulation
greater antitumor effect in combination with the vascular endo- of radiation response by histone deacetylase inhibition, Int J Radiat
thelial growth factor receptor tyrosine kinase inhibitor PTK787/ Oncol Biol Phys 62:223–229, 2005.
ZK222584, Cancer Res 64:6626–6634, 2004. 391. Wittenburg LA, Bisson L, Rose BJ, et al.: The histone deacety-
371. Michaelis M, Michaelis UR, Fleming I, et al.: Valproic acid inhib- lase inhibitor valproic acid sensitizes human and canine osteo-
its angiogenesis in vitro and in vivo, Mol Pharmacol 65:520–527, sarcoma to doxorubicin, Cancer Chemother Pharmacol 67:
2004. 83–92, 2011.
372. Rossig L, Li H, Fisslthaler B, et al.: Inhibitors of histone deacety- 392. Wittenburg LA, Gustafson DL, Thamm DH: Phase I pharmacoki-
lation downregulate the expression of endothelial nitric oxide syn- netic and pharmacodynamic evaluation of combined valproic acid/
thase and compromise endothelial cell function in vasorelaxation doxorubicin treatment in dogs with spontaneous cancer, Clin Can-
and angiogenesis, Circ Res 91:837–844, 2002. cer Res 16:4832–4842, 2010.